VYRIAD Trademark
VYRIAD is a USPTO trademark filed by Vyriad, Inc.. Status: Pending.
Trademark Facts
| Mark | VYRIAD |
|---|---|
| Serial Number | 98122765 |
| Status | Pending |
| Filing Date | 2023-08-08 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals), 042 (Software & IT) |
| Owner | Vyriad, Inc. |
| Attorney of Record | MICHELLE L. ZIMMERMANN |
| Prosecution Events | 19 |
| Latest Event | OP.D on 2025-05-07 |
Goods & Services
Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable genetic diseases; pharmaceutical preparations for treatment of genetic and heritable genetic diseases; cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical preparations for use in oncology; all of the foregoing to exclude infectious diseases; Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells (CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases